Gyroscope Merger Creates Gene Therapy Biotech For Eye Disorders
A new UK/US biotech tie-up makes a company with the technology to deliver its gene therapies.
You may also be interested in...
Fresh cash will help advance the UK firm's one-time investigational gene therapy for geographic atrophy and a listing in the US is in the offing.
Two preclinical antibodies targeted at stromal biology-associated immuno-oncology processes from Canada’s Northern Biologics have been acquired by Boehringer Ingelheim, which is also to collaborate with Switzerland’s CDR-Life on the development of a preclinical antibody fragment aimed at geographic atrophy associated with age-related macular degeneration.
Bringing gene therapy to the masses: company raises extra £50m in series B fundraising for novel dry macular degeneration treatment